With a better understanding of mechanisms of cancer progression, we have discovered more ways to treat tumors [61], among which immune checkpoint blockade (ICB) has been a great success and immune checkpoint inhibitors (ICI) are used as first-line therapy for advanced HCC, such as inhibition of CTLA-4 and PD-1 expression. Here, PDCD1 is linked to hepatocellular carcinoma.